18F-FDG PET-CT in the evaluation of paraneoplastic syndromes: Experience at a regional oncology centre

Nuclear Medicine Communications

Volumn 33, Issue 8, 2012, Pages 872-880

  Vaidyanathan, Sriram ^a   Pennington, Catherine ^b   Ng, Chen Yi ^a   Poon, Fat Wui ^a   Han, Sai ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b INSTITUTE OF NEUROLOGICAL SCIENCES   (United Kingdom)

Author keywords

computed tomography; malignancy; paraneoplastic syndromes; positron emission tomography

Indexed keywords

ANTI PARANEOPLASTIC NEUROLOGICAL MA PROTEIN; ANTI VOLTAGE GATED CALCIUM CHANNEL; ANTI VOLTAGE GATED POTASSIUM CHANNEL; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CORTICOTROPIN; FLUORODEOXYGLUCOSE F 18; HU ANTIBODY; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADULT; AGED; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ARTICLE; CANCER CENTER; CEREBELLUM DEGENERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DERMATOMYOSITIS; ENCEPHALOMYELITIS; FEMALE; FOLLOW UP; HUMAN; INTESTINE PSEUDOOBSTRUCTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC SYNDROME; PREDICTIVE VALUE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SENSORY NEUROPATHY; STIFF MAN SYNDROME; TUMOR BIOPSY; MIDDLE AGED; RETROSPECTIVE STUDY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PARANEOPLASTIC SYNDROMES; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84863423249     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283550237     Document Type: Article

References (16)

1. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75:1135-1140.
2. Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, et al. Screening for tumours in paraneoplastic syndromes: Report of an EFNS task force. Eur J Neurol 2011; 18:19-e3.
3. Candler PM, Hart PE, Barnett M, Weil R, Rees JH. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry 2004; 75:1411-1415.
4. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-Associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992; 71:59-72.
5. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50:652-657.
6. Chartrand-Lefebvre C, Howarth N, Grenier P, Keime F, Orcel B, Beigelman C. Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: Radiographic and CT findings. Am J Roentgenol 1998; 170:1513-1517.
7. Patel RR, Subramaniam RM, Mandrekar JN, Hammack JE, Lowe VJ, Jett JR. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: Value of positron emission tomography in diagnosis. Mayo Clin Proc 2008; 83:917-922.
8. Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004; 127 (Pt 10):2331-2338.
9. Bannas P,Weber C, Derlin T, Lambert J, Leypoldt F, Adam G, et al. 18F-FDGPET/CT in the diagnosis of paraneoplastic neurological syndromes: A retrospective analysis. Eur Radiol 2010; 20:923-930.
10. Hadjivassiliou M, Alder SJ, Van Beek EJ, Hanney MB, Lorenz E, Rao DG, et al. PET scan in clinically suspected paraneoplastic neurological syndromes: A 6-year prospective study in a regional neuroscience unit. Acta Neurol Scand 2009; 119:186-193.
11. McKeon A, Apiwattanakul M, Lachance DH, Lennon VA, Mandrekar JN, Boeve BF, et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: Systematic analysis and review. Arch Neurol 2010; 67:322-329.
12. Rees JH, Hain SF, Johnson MR, Hughes RA, Costa DC, Ell PJ, et al. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001; 124 (Pt 11): 2223-2231.
13. Titulaer MJ,Wirtz PW,Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: A follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008; 26:4276-4281.
14. Honnorat J. Onconeural antibodies are essential to diagnose paraneoplastic neurological syndromes. Acta Neurol Scand Suppl 2006; 183:64-68.
15. Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: Value of CT and PET for tumor diagnosis. Neurology 2004; 63:282-286.
16. The Royal College of Radiologists. Recommendations for cross-sectional imaging in cancer management. Ref no. RCR (06)1. London: The Royal College of Radiologists; 2006.